D-0355-2026 Class II Ongoing

Recalled by Teva Pharmaceuticals USA, Inc — Parsippany, NJ

FDA drug recall D-0355-2026 was initiated by Teva Pharmaceuticals USA, Inc on Jan 29, 2026 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is ongoing. Affected quantity: 67,043 bottles.

Recall Details

Product Type
Drugs
Report Date
Mar 11, 2026
Initiation Date
Jan 29, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
67,043 bottles

Product Description

Metoprolol Succinate Extended-Release Tablets, 50 mg, 100 tablets bottles (NDC: 45963-676-11) and 1,000 tablets bottles (NDC: 45963-676-96), Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054

Reason for Recall

Failed Dissolution Specifications

Distribution Pattern

Nationwide

Code Information

Lot#: a) 0486G251, 0487G251, 0488G251, Exp.: 01/2027; b) 0486G252, 0487G253, 0488G252, Exp.: 01/2027.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0355-2026
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0355-2026. Report a data issue: hello@regdatalab.com.